Skip to Content
Merck
CN
All Photos(1)

Documents

1269618

USP

Fenofibrate Related Compound B

United States Pharmacopeia (USP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic acid, Fenofibric acid
Empirical Formula (Hill Notation):
C17H15ClO4
CAS Number:
42017-89-0
Molecular Weight:
318.75
Beilstein:
2058973
MDL number:
MFCD00792461
UNSPSC Code:
41116107
PubChem Substance ID:
329749839
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

fenofibrate

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O=C(C1=CC=C(OC(C)(C)C(O)=O)C=C1)C2=CC=C(Cl)C=C2

InChI

1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)

InChI key

MQOBSOSZFYZQOK-UHFFFAOYSA-N

Gene Information

human ... PPARA(5465)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fenofibrate Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1269447

Fenofibrate, United States Pharmacopeia (USP) Reference Standard

F0048005

Fenofibrate impurity A, European Pharmacopoeia (EP) Reference Standard

1269607

Fenofibrate Related Compound A, United States Pharmacopeia (USP) Reference Standard

F0048010

Fenofibrate impurity B, European Pharmacopoeia (EP) Reference Standard

1269629

Fenofibrate Related Compound C, United States Pharmacopeia (USP) Reference Standard

F0048035

Fenofibrate impurity G, European Pharmacopoeia (EP) Reference Standard

PHR1246

Fenofibrate, Pharmaceutical Secondary Standard; Certified Reference Material

1133558

Choline Fenofibrate, United States Pharmacopeia (USP) Reference Standard

PHR2864

Fenofibrate Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

Exclamation markEnvironment
GHS07,GHS09

Signal Word

Warning

Hazard Statements

H302,H410

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1

WGK

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Roger K Verbeeck et al.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 18(1), 61-67 (2015-04-17)
The therapeutic equivalence of multiple registered fenofibrate formulations, several of which are suprabioavailable and therefore marketed at lower dosage strengths than their reference products, is based on the results of bioequivalence studies. Most of these formulations show a higher bioavailability
Yunxia Lu et al.
Biochemical and biophysical research communications, 458(1), 1-7 (2015-01-17)
Fenofibrate (FF) is widely used to lower blood lipids in clinical practice, but whether its protective effect on endothelium-dependent vasodilatation (EDV) in thoracic aorta is related with endoplasmic reticulum (ER) stress remains unknown. In this study, female Sprauge Dawley rats
Martin J A Schackmann et al.
Biochimica et biophysica acta, 1851(2), 231-237 (2014-12-17)
X-linked adrenoleukodystrophy (X-ALD) is a neurometabolic disease that is caused by mutations in the ABCD1 gene. ABCD1 protein deficiency impairs peroxisomal very long-chain fatty acid (VLCFA) degradation resulting in increased cytosolic VLCFA-CoA levels, which are further elongated by the VLCFA-specific

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service